

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 855 389 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

29.07.1998 Bulletin 1998/31

(51) Int Cl.⁶: C07C 405/00, A61K 31/557

(21) Application number: 98300513.3

(22) Date of filing: 26.01.1998

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 27.01.1997 JP 27198/97

(71) Applicant: ONO PHARMACEUTICAL CO., LTD.
Chuo-ku Osaka 541 (JP)


(72) Inventors:

- Maruyama, Toru,
c/o Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)
- Ohuchida, Shuichi,
Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)

(74) Representative: Bentham, Stephen
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)

(54) **A 3,7-dithiaprostanoid acid derivative**

(57) A 3,7-dithiaprostanoid acid derivative of the formula (I)



(wherein R¹ is OH, C1-4 alkoxy, NR⁶R⁷ (wherein R⁶, R⁷ are H, C1-4); R² is H, OH; R³ is (i) alkyl, alkenyl, alkynyl (ii) phenyl, cycloalkyl (iii) alkyl, alkenyl, alkynyl substituted by phenyl, cycloalkyl (when R² is H, alkyl, alkenyl, alkynyl in (i) or (iii) may be substituted by OH) possesses a binding activity for PGE₂ receptor (especially for EP4). Therefore they are useful for the treatment and/or prevention of immunologic diseases (autoimmune diseases, organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, liver damage, nephritis, hypertension, myocardial ischemia etc.

EP 0 855 389 A2

Description

Summary

5 The present invention provides 3,7-dithiaprostanic acid derivatives, processes for the preparation of them and pharmaceutical compositions containing them.

Background

10 Prostaglandin E₂ (abbreviated as PGE₂ hereafter) has been known as a metabolite in the arachidonate cascade. Its known activities include cyto-protective activity, uterine contractile activity, a pain-inducing effect, a promoting effect on digestive peristalsis, an awakening effect, a suppressive effect on gastric acid secretion, hypotensive activity and diuretic activity etc. In recent study, it was found that PGE₂ receptor was divided into some subtypes which possess different physiological role from each other. At present, four receptor subtypes are known and they are called EP1, EP2, EP3 and EP4 (Negishi M. et al, J. Lipid Mediators Cell Signalling 12, 379-391 (1995)).

15 The present inventors investigated to find compounds which bind to each receptor specifically; we found that the compounds of the present invention could bind strongly to EP4 subtype receptor and then achieved the present invention.


20 The compound of formula (I) possess a binding activity for EP4 subtype receptor strongly. Therefore they are useful for the treatment and/or prevention of immunologic diseases (autoimmune diseases, immunological deficiency diseases, organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, liver damage, nephritis, hypertension, myocardial ischemia etc.

25 Among the compounds of the present invention of the formula (I), compounds which bind weakly to receptor subtypes except for EP4 receptors do not express other effects and therefore it is thought that such compounds will be a medical agent which have less side-effects.

On the other hand, many modified PGs wherein 7th position carbon atom is replaced by sulfur atom are known. The following application is mentioned for an example.

30 In the specification of Japanese Kokai No. 57-108065 (i.e. EP 51284), the following compounds are disclosed as an agent for anti-platelets aggregation.

I.e. 7-thiaprostaglandin derivatives of the formula (A):



40 (wherein R^{1A} is hydrogen atom, lower alkyl or pharmaceutically acceptable cation,
R^{2A} is hydrogen atom or methyl,

R^{3A} is C5-7 alkyl or cycloalkyl,

R^{4A} and R^{5A} is hydrogen atom or a protective group for hydroxy.

45 Symbol * means the existence of an asymmetric carbon, its stereo configuration is α , β or a mixture thereof in voluntary ratio.)

In the specification of Japanese Kokai No. 58-148857, the following compounds are disclosed as an agent for anti-platelet aggregation.

50 I.e. 7-thiaprostaglandin derivatives of the formula (B):



10

15




30

50

Disclosure of the Invention

55



(wherein R¹ is hydroxy, C1-4 alkoxy or a group of the formula:



wherein R⁶ and R⁷, independently, are hydrogen atom or C1-4 alkyl,
R² is hydrogen atom or hydroxy,
R³ is

- (i) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl,
- (ii) phenyl or C3-7 cycloalkyl,
- (iii) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by phenyl or C3-7 cycloalkyl,

with the proviso that, alkyl, alkenyl, alkynyl in (i) or (iii) may be substituted by one hydroxy group, when R² is hydrogen atom;

the symbol --- is a double or single bond;
the formula including the 8-epi equilibrium compound thereof);
a non-toxic salt thereof or a cyclodextrin clathrate thereof.

In the formula (I), C1-4 alkoxy represented by R¹ means methoxy, ethoxy, propoxy, butoxy groups and isomeric groups thereof.

In the formula (I), C1-4 alkyl represented by R⁶ and R⁷ means methyl, ethyl, propyl, butyl groups and isomeric groups thereof.

In the formula (I), C1-8 alkyl represented by R³ and in R³ means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl groups and isomeric groups thereof.

In the formula (I), C2-8 alkenyl represented by R³ and in R³ means vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl groups and isomeric groups thereof.

In the formula (I), C2-8 alkynyl represented by R³ and in R³ means ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl groups and isomeric groups thereof.

In the formula (I), C3-7 cycloalkyl represented by R³ and in R³ means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl.

In this specification the symbol:



indicates a double or single bond, unless otherwise specified, the tapered line:



indicates that the substituent attached thereto is in front of the sheet, the symbol:



indicates that the substituent attached thereto is behind the sheet, the symbol:

5 or

10 indicates that the substituent attached thereto is a mixture of in front of and behind the sheet or may be in front of or behind the sheet.

Unless otherwise specified, all isomers are included in the invention. For example, alkyl, alkylene and alkenylene includes straight-chain and branched-chain. Double bond in alkenylene includes E, Z and EZ mixtures. Isomers generated by the existence of asymmetric carbon(s) e.g. in branched alkyl are included in the present invention.

15 Among the compounds of the present invention, preferred configuration of compounds wherein R² is hydroxy in α -configuration i.e. natural configuration.

The configuration of 8th position of the compounds of the present invention are shown as α , but as is known in the art, these 8 α -compounds are an equilibrium state with 8 β -compounds (8-epi compound). Therefore the compounds of the formula (I) mean mixture of 8 α -compound and isomeric 8 β -compound.

20 Among the compounds of the present invention of the formula (I), preferred compounds are compounds shown in examples, the following compounds and corresponding esters and amides.

25

30

35

40

45


50

55

Table 1

(1)




5






10






15






20






25





30






35






40



45



50



55

Table 2

(2)






























Table 3

(3)

5





10



15





20





25





30





35



40



45



50

55

Table 4

(4)

















Table 5

(5)

5





10



15





20





25





30





35



40



45




50

55

Table 6

(6)

5





10



15





20





25





30





35



40



45




50

55

Table 7

(7)

5





10



15





20





25





30





35



40



45



50

55

Table 8

(8)

















Table 9

(9)

5






10




15






20





25






30






35






40



45



50



55

(10)




























Table 11

(11)

5




10



15




20





25





30



35



40



45

50

55

(12)






Table 13

(13)

5





10



15




20





25





30



35



40



45


50

55

Table 14

(14)

5





10



15




20





25





30



35



40



45


50

55

Table 15

(15)

5





10



15




20





25





30



35



40













45

50

55

Table 16

(16)



Salts

The compounds of the formula (I) may be converted into the corresponding salts. Non-toxic and water-soluble salts are preferable. Suitable salts, for example, are as follows: salts of alkali metal (sodium, potassium etc.), salts of alkaline earth metal (calcium, magnesium etc.), ammonium salts, salts of pharmaceutically acceptable organic amine (tetramethylammonium, triethylamine, methylamine, dimethyl-


amine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)aminomethane, lysine, arginine, N-methyl-D-glucamine etc.).

5 Cyclodextrin clathrates


Cyclodextrin clathrates of 3,7-dithiapropanoic acid derivatives of the formula (I) may be prepared by the method described in GB 1351238 using α -, β - or γ -cyclodextrin or a mixture thereof. Converting into their cyclodextrin clathrates serves to increase the stability and solubility in water of the compounds, and therefore it is useful in the use for pharmaceuticals.

Processes for the Preparation

(1) Among the compounds of the formula (I), compounds of formula (Ia):




(wherein all symbols are the same meaning as hereinbefore defined.)
may be prepared by hydrolyzing a compound of formula (Ib):




(wherein R^{10} is C1-4 alkyl and the other symbols are the same meaning as hereinbefore defined.)
with an enzyme.

Hydrolysis with an enzyme is known, for example, it may be carried out in a mixture of a water-miscible organic solvent (ethanol, dimethylsulfoxide etc.) and water, in the presence or absence of buffer, using an ester cleaving enzyme (esterase, lipase etc.), at 0-50 °C.

(2) Among the compounds of the formula (I), compounds of formula (Ic):



(wherein all symbols are the same meaning as hereinbefore defined.)
may be prepared by amidation of a compound of the formula (Ia):




(wherein all symbols are the same meaning as hereinbefore defined.)
with a compound of formula (III):




(wherein all symbols are the same meaning as hereinbefore defined.).

Amidation is known reaction, for example, in an inert organic solvent (tetrahydrofuran (THF), methylene chloride, benzene, acetone, acetonitrile or a mixture thereof etc.), in the presence or absence of tertiary amine (dimethylaminopyridine, pyridine, triethylamine etc.), using a condensing agent (1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC), 1,3-dicyclohexylcarbodiimide (DCC) etc.), at 0-50 °C.

(3) Among the compounds of the formula (I), compounds of the formula (Ib):



(wherein all symbols are the same meaning as hereinbefore defined.)
may be prepared by hydrolyzing a compound of formula (II):



(wherein R^{2a} is hydrogen atom or hydroxy protected by a protecting group which is eliminated under an acidic condition, R^{20} is a protecting group which is eliminated under an acidic condition, R^{3a} is (i) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl, (ii) phenyl or C3-7 cycloalkyl, (iii) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl which are substituted by phenyl or C3-7 cycloalkyl (with the proviso that when R^{2a} is hydrogen, alkyl, alkenyl and alkynyl groups in (i) or (iii) may be substituted by hydroxy protected by a protecting group which is eliminated under an acidic condition); the symbol:

is a double or single bond)
in an acidic condition.

A protecting group which is eliminated under an acidic condition means, for example, t-butyldimethylsilyl, triphenylsilyl, triphenylmethyl, tetrahydropyranyl, 1-ethoxyethyl, methoxymethyl, trimethylsilyl, etc.


Hydrolysis under an acidic condition is known, for example, in a water-miscible organic solvent (THF, methanol, ethanol, dimethoxyethane, acetonitrile or a mixture thereof etc.), using inorganic acid (hydrochloric acid, phosphoric

acid, hydrofluoric acid, hydrogen fluoride-pyridine complex etc.) or organic acid (acetic acid, toluenesulphonic acid, trichloroacetic acid etc.), at 0-50 °C.

The compound of the formula (II) may be prepared by the following reaction scheme (A) in the next sheet.

Symbols in reaction scheme are the same meaning as hereinbefore defined.

Scheme (A)



In each reaction in this specification products may be purified by conventional manner. For example, it may be carried out by distillation under atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization. Purification may be carried out after each reaction, or after a series of reactions.

Starting Materials and Reagents

Starting materials and reagents are known per se or may be prepared by known methods.

Properties of the Compound of the Invention

The compounds of the present invention of the formula (I) bind and act on EP4 receptor which is a subtype of PGE_2 receptor.

In a standard laboratory test, the activities of the compounds of the present invention were confirmed by binding

assay using expression cell of the prostanoid receptor subtype.

(I) Binding assay using expression cell of the prostanoid receptor subtype

5 The preparation of membrane fraction was carried out according to the method of Sugimoto et al (J. Biol. Chem. 267, 6463-6466 (1992)) using the prostanoid receptor subtypes (mouse EP3 α , EP4) expressing CHO cells.

10 The standard assay mixture containing membrane fraction (0.5 mg/ml) and ^3H -PGE $_2$ in a final volume of 200 μl was incubated for 1 hour at room temperature. The reaction was terminated by the addition of 3 ml of ice-cold buffer. The mixture was rapidly filtered through a GF/B glass filter. The radioactivity associated with the filter was measured by liquid scintillation counting.

Kd and Bmax value were determined from Scatchard plots (Ann. N. Y. Sci., 51, 660 (1949)). Non-specific binding was calculated as the bound in the presence of an excess (2.5 μM) of unlabeled PGE $_2$.

15 In the experiment for competition of specific ^3H -PGE $_2$ binding by the compounds of the present invention, 2.5nM of ^3H -PGE $_2$ and various concentration of the compounds of the present invention were added. The following buffer was used in all reactions. Buffer: 10 mM potassium phosphate (pH 6.0), 1 mM EDTA, 10 mM MgCl $_2$, 0.1 M NaCl. The dissociation constant (Ki) of each compound was calculated by the following equation.

$$K_i = IC_{50} / (1 + [C]/K_d)$$

20 Results are shown in Table 17 and 18.

Table 17

Example No.	Dissociation constant for EP4 Ki (μM)
2	0.0007
2(a)	0.0008
2(b)	0.0006
2(c)	0.0056
2(d)	0.0016
2(e)	0.00091
2(f)	0.007
2(g)	0.006
2(h)	0.022
2(k)	0.0007
2(m)	0.0014
2(o)	0.0002
2(q)	0.0004
2(t)	0.0042

Table 18

Example No.	Dissociation constant for EP3 α Ki (μM)
2	1.5
2(a)	0.01
2(f)	0.13
2(h)	0.61
2(k)	0.034
2(m)	0.023
2(o)	0.025

55 Toxicity

On the other hand, toxicity of the compounds of the present invention of the formula (I) are very low, and are therefore, it may be estimated to be safe for pharmaceutical use.

Application for Pharmaceu

The compounds of the present invention of the formula (I) bind strongly and act on PGE₂ receptor, especially on EP4 subtype receptor and therefore are useful for prevention and/or treatment of immunologic diseases (autoimmune diseases, immunological deficiency diseases, organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, liver damage, nephritis, hypertension, myocardial ischemia etc.

Among the compounds of the present invention of the formula (I), compounds which bind weakly to receptor subtypes except for EP4 receptors do not express other effects and therefore it is thought that such compounds will be a medical agent which have less side-effects.

For the purpose described above, the compounds of the present invention of the formula (I), non-toxic salts thereof or cyclodextrin clathrates thereof may be normally administered systemically or locally, usually by oral or parenteral administration.

The doses to be administered are determined depending upon age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment etc. In the human adult, the doses per person per dose are generally between 1 µg and 100 mg, by oral administration, up to several times per day, and between 0.1 µg and 10 mg, by parenteral administration up to several times per day, or continuous administration between 1 and 24 hrs. per day from vein.

As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

When administration of the compounds of the present invention, it is used as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parenteral administration. Solid compositions for oral includes tablets, pills, capsules, dispersible powders, granules. Capsules include soft capsules and hard capsules.

In such compositions, one or more of the active compound(s) is or are, admixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone or magnesium metasilicate aluminate.

The compositions may also comprise, as is normal practice, additional substances other than inert diluents e.g. lubricating agents such as magnesium stearate, disintegrating agents such as cellulose calcium glycolate, stabilizing agents e.g. lactose and agents to assist dissolution e.g. arginine, glutamic acid or aspartic acid. The tablets or pills may, if desired, be made into gastric film-coated tablets or pills, such as sugar-coated, gelatin-coated, hydroxypropyl cellulose-coated hydroxypropylmethyl cellulose phthalate-coated tablets or pills; two or more layers may be used. The compositions for oral administration also include capsules of absorbable material such as gelatin.

Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as distilled water or ethanol. Besides inert diluents such compositions may also comprise adjuvants such as wetting and suspending agents, and sweetening, flavoring, perfuming and preserving agents.

Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (sodium sulfate etc.), isotonic buffer (sodium chloride, sodium citrate, citric acid etc.). For preparation of such spray compositions, for example, the method described in the U. S. Patent No. 2,868,691 or U. S. Patent No. 3,095,355 may be used.

Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Aqueous solutions, suspensions include distilled water for injection and physiological salt solution. Non-aqueous solutions, suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, alcohol such as ethanol, POLYSORBETE 80 (registered trade mark), etc.

Such compositions may comprise additives other than inert diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agents, assisting agents such as assisting agents for dissolving (glutamic acid, aspartic acid etc.). They may be sterilized, for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They may also be manufactured in the form of sterile solid compositions and which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before used.

Other compositions for parenteral administration include liquids for external use, and endermic liniments, ointment, suppositories for rectal administration and pessaries for vaginal administration which comprise one or more of the active compound(s) and may be prepared by per se known methods.


Reference Examples and Examples

The following reference examples and examples illustrate the present invention, but not limit the present invention.

The solvents in parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations. Unless otherwise specified "NMR" were measured in a solution of CDCl_3 .

Reference Example 1

2,2-dibutyl-2-stanane-1,3-dithiane




A solution of 1,3-propanedithiol (3.0 g) and dibutyl stanane oxide (6.9 g) in benzene was refluxed. The reaction mixture was evaporated to give the title compound having the following physical data.

TLC : Rf 0.68 (hexane:EtOAc=9:1).

Reference Example 2

6-Mercapto-3-thiahexanoic acid methyl ester




Bromoacetic acid methyl ester (6.36 g) was added to a solution of 2,2-dibutyl-2-stanane-1,3-dithiane (9.38 g) in anhydrous dimethylformamide (DMF, 20 ml). The mixture was stirred for 3 hrs at 100 °C. After cooling, water was added to the reaction mixture. The mixture was stirred for 1 hr. The reaction mixture was extracted with ethyl acetate. The organic layer was washed, dried and evaporated. The residue was purified by column chromatography on silica gel (hexane-ethyl acetate) to give the title compound (2.61 g) having the following physical data.

TLC : Rf 0.60 (hexane:EtOAc=4:1).

Reference Example 3

7-(4R-t-butyldimethylsilyloxycyclopentenon-2-yl)-3,7-dithiaheptanoic acid methyl ester




4R-t-butyldimethylsilyloxy-2-cyclopentenone (2.76 g) in methanol (40 ml) was cooled with ice. An aq. solution of hydroperoxide (31%, 5 ml) and a 1N aq. solution of sodium hydroxide (0.05 ml) were added to the solution. The mixture was stirred for 1.5 hrs at the same temperature. Saturated aq. solution of ammonium chloride was added to the reaction mixture and the mixture was extracted. The organic layer was washed, dried and evaporated. The residue was dissolved in chloroform (35 ml). A solution of 6-mercapto-3-thiahexanoic acid methyl ester (2.34 g) in chloroform (10 ml) and active alumina (13 g) were added to the solution. The mixture was stirred overnight at room temperature. The reaction mixture was filtered. The filtrate was evaporated and purified by column chromatography on silica gel (hexane-ethyl acetate) to give the title compound (3.21 g) having the following physical data.

TLC : Rf 0.39 (hexane:EtOAc=4:1).

Reference Example 4

11 α ,15 α -bis(t-butyltrimethylsilyloxy)-9-oxo-3,7-dithiaprost-13-enoic acid methyl ester




Under an atmosphere of argon, 1.57M solution of t-butyl lithium in pentane (1.01 ml) was dropped to a solution of (3S)-1-iodo-3-t-butyltrimethylsilyloxy-1-octene (290 mg) in anhydrous ether (4 ml). The mixture was stirred for 1 hr at the same temperature. A 0.25 M solution of lithium copper 2-thienylcyanide in THF (3.38 ml) was dropped to the solution at -78 °C. The reaction mixture was stirred for 30 mins at the same temperature. A solution of 7-(4R-t-butyltrimethylsilyloxycyclopentenon-2-yl)-3,7-dithiaheptanoic acid methyl ester (220 mg; prepared in Reference Example 3) in anhydrous THF (4 ml) was dropped to the solution at -78 °C. The reaction mixture was stirred for 1 hr. An aq. saturated solution of ammonium chloride was added to the mixture. The mixture was warmed to room temperature. The reaction mixture was extracted by hexane. The organic layer was washed, dried, evaporated and purified by column chromatography on silica gel (hexane-ethyl acetate) to give the title compound (258 mg) having the following physical data.

TLC : Rf 0.55 (hexane:EtOAc=4:1).

Example 1

11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprost-13E-enoic acid methyl ester




Pyridine (1.2 ml) and hydrogen fluoride-pyridine (2 ml) were added to a solution of 11 α ,15 α -bis(t-butyltrimethylsilyloxy)-9-oxo-3,7-dithiaprost-13E-enoic acid methyl ester (220 mg; prepared in Reference Example 4) in acetonitrile (8 ml) cooled with ice. The reaction mixture was stirred for 1 hr at room temperature. The reaction mixture was poured into a mixture of ethyl acetate and an aq. saturated sodium bicarbonate cooled at 0 °C. The mixture was extracted with ethyl acetate. The organic layer was washed, dried and evaporated. The residue was purified by column chromatography on silica gel (chloroform-methanol) to give the title compound (123 mg; equilibrium mixture with 8-epi compound) having the following physical data.

TLC: Rf 0.55 (CHCl₃:CH₃OH = 19:1);

NMR : δ 5.73 (1H, dd), 5.63 (1H, dd), 4.44 and 4.13 (2H, each m), 3.74 (3H, s), 3.23 (2H, s), 3.40-2.18 (8H, m), 1.98-1.20 (10H, m), 0.90 (3H, t).

Example 2

11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprost-13E-enoic acid



Phosphate buffer (10 ml; pH 7.4) was added to a solution of 11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprost-13E-enoic acid methyl ester (48 mg; prepared in Example 1) in ethanol (1 ml). Pig liver esterase was added to the reaction mixture. The mixture was stirred for 2 hrs at room temperature. A saturated aq. solution of ammonium sulfate was added to the mixture. The mixture was extracted by ethyl acetate. The organic layer was dried, evaporated. The residue was purified by column chromatography on silica gel (ethyl acetate) to give the title compound (39 mg; an equilibrium mixture with 8-epi isomer) having the following physical data.

TLC : Rf 0.10 (EtOAc);


NMR : δ 5.79 (1H, dd), 5.64 (1H, dd), 4.3-4.1 (2H, m), 3.7 (1H, bs), 3.23 (2H, s), 3.0-2.4 (8H, m), 2.0-1.8 (2H, m), 1.7-1.5 (2H, m), 1.4-1.2 (6H, m), 1.0-0.8 (3H, m).

Example 2(a)-2(u)

Compounds having the following physical data were given by the same manner in Reference Example 4, Example 1 and 2. These compounds are equilibrium mixtures with 8-epi isomers.

Example 2(a)

11 α ,15 α -dihydroxy-9-oxo-17 β ,20-dimethyl-3,7-dithiaprost-13E-enoic acid




TLC : Rf 0.50, 0.44 (CHCl₃:CH₃OH=9:1, 1% acetic acid);

NMR : δ 5.75(2H, m), 5.06(3H, br), 4.53-4.05(2H, m), 3.42-2.18(8H, m), 3.23(2H, s), 1.88(2H, m), 1.58(2H, m), 1.42-1.03(7H, m), 0.91(6H, m).

Example 2(b)


11 α ,15 α -dihydroxy-9-oxo-17 α ,20-dimethyl-3,7-dithiaprost-13E-enoic acid




TLC : Rf 0.38, 0.22 (EtOAc:AcOH=100:1);

NMR : δ 5.74 (1H, dd), 5.67 (1H, dd), 4.77 (3H, br), 4.45 and 4.20(2H, each m), 3.23 (2H, s), 3.42-2.18 (8H, m), 1.88 (2H, m), 1.62-1.04 (9H, m), 0.89 (6H, m).


Example 2(c)

11 α ,16 β -dihydroxy-9-oxo-16 α -methyl-3,7-dithiaprost-13E-enoic acidTLC : R_f 0.30, 0.23 (EtOAc:hexane:AcOH=6:2:1);NMR : δ 5.9-5.7 (1H, m), 5.7-5.5 (1H, m), 4.5 and 4.1 (1H, each m), 4.1-3.7 (3H, br), 3.55-3.45 and 3.2-2.2 (10H, each m), 3.24 (2H, s), 2.0-1.8 (2H, m), 1.6-1.1 (6H, m), 1.23 (3H, s), 0.93 (3H, t).

Example 2(d)


11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprostanoic acidTLC : R_f 0.30 (EtOAc:AcOH=100:1);NMR : δ 5.25 (3H, br), 4.32 and 4.15 (1H, each m), 3.72 (1H, m), 3.23 (2H, s), 3.38-2.38 (7H, m), 2.24 (1H, m), 2.08-1.12 (14H, m), 0.90 (3H, t).

Example 2(e)

11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprost-13E,17Z-dienoic acidTLC : R_f 0.52, 0.41 (EtOAc:AcOH=20:1);NMR : δ 5.9-5.5 (3H, m), 5.5-5.2 (1H, m), 4.6-4.2 (5H, br), 3.24 (2H, s), 3.45-3.40 and 3.1-2.2 (8H, each m), 2.2-2.0 (2H, m), 2.0-1.8 (2H, m), 0.97 (3H, t).

Example 2(f)

11 α ,15 α -dihydroxy-9-oxo-16-phenyl-17,18,19,20-tetranor-3,7-dithiaprost-13E-enoic acid




TLC : Rf 0.24 (EtOAc:CH₃OH=2:1);

NMR : δ 7.38-7.16 (5H, m), 5.90-5.50 (2H, m), 4.56-3.70 (7H, m), 3.21 (2H, s), 3.10-2.26 (10H, m), 1.87 (2H, quin.).

Example 2(g)

11α,15α-dihydroxy-9-oxo-17-phenyl-18,19,20-trinor-3,7-dithiaprost-13E-enoic acid




TLC : Rf 0.52, 0.43 (EtOAc:AcOH=20:1);

NMR: δ 7.35-7.15 (5H, m), 5.9-5.6 (2H, m), 4.5-4.4 and 4.3-4.0 (2H, each m), 4.3-3.6 (3H, br), 3.03 (2H, s), 3.45-3.40 and 3.05-2.20 (10H, each m), 2.0-1.8 (4H, m).

Example 2(h)

11α,15α-dihydroxy-9-oxo-15-cyclohexyl-3,7-dithia-16,17,18,19,20-pentanorprost-13E-enoic acid




TLC : Rf 0.46, 0.40 (CHCl₃:CH₃OH=9:1, 1% AcOH);

NMR : δ 5.77 (1H, m), 5.61 (1H, dd), 4.76 (3H, br), 4.45 and 4.14 (1H, each m), 3.92 (1H, m), 3.42-2.30 (8H, m), 3.23 (2H, s), 1.98-1.56 (7H, m), 1.54-0.85 (6H, m).

Example 2(i)

11α,15α-dihydroxy-9-oxo-15-cyclopentyl-3,7-dithia-16,17,18,19,20-pentanorprost-13E-enoic acid




TLC : R_f 0.27 (CHCl₃/Me₂SO, 4/1);

NMR : δ 5.86-5.48 (2H, m), 4.70-3.20 (6H, m), 3.15 (2H, s), 3.08-1.00 (18H, m).

Example 2(j)

11 α ,15 α -dihydroxy-9-oxo-16-cyclohexyl-3,7-dithia-17,18,19,20-tetranorprost-13E-enoic acid




TLC R_f : 0.22 (AcOEt/AcOH, 50/1);

NMR : δ 5.90-5.52 (2H, m), 5.04-4.40 (3H, br), 4.40-3.92 (3H, m), 3.22 (2H, s), 3.12-2.24 (7H, m), 2.24-0.70 (15H, m).

Example 2(k)

11 α ,15 α -dihydroxy-9-oxo-15 β -methyl-3,7-dithiaprost-13E-enoic acid




TLC : R_f 0.27 (AcOEt/AcOH, 50/1);

NMR : δ 5.84-5.46 (2H, m), 5.36-4.70 (3H, br), 4.47-3.98 (2H, m), 3.15 (2H, s), 3.06-2.20 (7H, m), 2.04-1.72 (2H, m), 1.60-1.40 (2H, m), 1.32-1.10 (9H, m), 0.81 (3H, t, J=6.4Hz).

Example 2(l)

11 α ,15 α -dihydroxy-9-oxo-17-ethyl-3,7-dithia-20-norprost-13E-enoic acid




TLC : R_f 0.49, 0.38 (EtOAc/AcOH, 20:1);

NMR : δ 5.9-5.6 (2H, m), 5.6-5.0 (3H, br), 4.6-4.0 (2H, m), 3.23 (2H, s), 3.45-3.40 and 3.1-2.2 (8H, m), 2.0-1.8 (2H, m), 1.6-1.2 (7H, m), 0.83 (6H, t, J=7 Hz).

Example 2(m)

11 α ,15 α -dihydroxy-9-oxo-3,7-dithia-20-norprost-13E-enoic acid




TLC : Rf 0.47, 0.37 (EtOAc/AcOH, 20:1);

NMR: δ 5.85-5.60 (2H, m), 5.6-5.2 (3H, br), 4.5-4.4 and 4.25-4.05 (2H, m), 3.23 (2H, s), 3.45-3.40 and 3.1-2.2 (8H, m), 2.0-1.8 (2H, m), 1.7-1.2 (6H, m), 0.92 (3H, t, J=7Hz).

Example 2(n)

11 α ,15 α -dihydroxy-9-oxo-3,7-dithia-20-homoprost-13E-enoic acid




TLC : Rf 0.58, 0.46 (EtOAc/AcOH, 10/1);

NMR: δ 5.71 (2H, m), 5.38 (3H, br), 4.45 and 4.17 (2H, each m), 3.42 and 3.03 (1H, each d, J=6.6 and 11Hz), 3.23 (2H, s), 2.98-2.20 (7H, m), 1.88 (2H, m), 1.54 (2H, m), 1.48-1.15 (8H, m), 0.89 (3H, t, J=6.4Hz).

Example 2(o)

11 α ,15 α -dihydroxy-9-oxo-16 β -methyl-3,7-dithiaprost-13E-enoic acid




TLC : Rf 0.53, 0.42 (EtOAc/AcOH, 20:1);

NMR: δ 5.85-5.60 (2H, m), 4.5-4.4 and 4.2-4.0 (2H, m), 4.6-3.8 (3H, br), 3.22 (2H, s), 3.45-3.40 and 3.1-2.2 (8H, m), 2.0-1.8 (2H, m), 1.7-1.1 (7H, m), 1.0-0.8 (6H, m).

Example 2(p)

11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprost-13E,19-dienoic acid




TLC : Rf 0.62, 0.56 (EtOAc/AcOH, 20/1);

NMR : δ 5.88-5.48 (6H, m), 5.00 (2H, m), 4.42 and 4.15 (2H, each m), 3.40 and 3.02 (1H, each d, J=6.6 and J=11Hz), 3.22 (2H, s), 3.06-2.28 (7H, m), 2.08 (2H, m), 1.86 (2H, m), 1.52 (4H, m).

Example 2(q)

11 α , 15 α -dihydroxy-9-oxo-19,20-methano-3,7-dithiaprost-13E-enoic acid




TLC : Rf 0.37, 0.19 (EtOAc/AcOH, 20/1);

NMR : δ 5.74 (5H, m), 4.44 and 4.15 (2H, each m), 3.41 and 3.02 (1H, each d, J=6.8Hz and J= 11Hz), 3.23 (2H, s), 2.98-2.19 (7H, m), 1.86 (2H, m), 1.73-1.10 (6H, m), 0.63 (1H, m), 0.40 (2H, m), 0.00 (2H, m).

Example 2(r)

11 α , 15 α -dihydroxy-9-oxo-18-methyl-3,7-dithia-20-norprost-13E-enoic acid




TLC : Rf 0.50, 0.27 (EtOAc/AcOH, 20/1);

NMR : δ 5.68 (5H, m), 4.44 and 4.15 (2H, each m), 3.42 and 3.03 (1H, each d, J=6.6Hz and J= 11Hz), 3.23 (2H, s), 2.98-2.20 (7H, m), 1.88 (2H, m), 1.57 (3H, m), 1.23 (2H, m), 0.90 (6H, d, J=6.6Hz).

Example 2(s)


11 α , 15 α -dihydroxy-9-oxo-16 α -methyl-3,7-dithiaprost-13E-enoic acid



TLC : Rf 0.49, 0.39 (EtOAc/AcOH, 20:1);
 NMR : δ 5.9-5.6 (2H, m), 4.5-4.4 and 4.3-4.0 (2H, m), 4.7-3.9 (3H, br), 3.23 (2H, s), 3.45-3.40 and 2.9-2.2 (8H, m), 2.0-1.8 (2H, m), 1.7-1.0 (7H, m), 1.0-0.8 (6H, m).

Example 2(t)


11 α ,15 α -dihydroxy-9-oxo-16-cyclopentyl-3,7-dithia-17,18,19,20-tetranorprost-13E-enoic acid



TLC : Rf 0.53, 0.37 (EtOAc/AcOH, 20/1);
 NMR : δ 5.76 (5H, m), 4.44 and 4.18 (2H, each m), 3.42 and 3.03 (1H, each d, J=6.8Hz and J=11Hz), 3.23 (2H, s), 2.96-2.20 (7H, m), 2.01-1.38 (11H, m), 1.13 (2H, m).

Example 2(u)

11 α ,15 α -dihydroxy-9-oxo-16 α -methyl-16-phenyl-3,7-dithia-20-norprost-13E-enoic acid



TLC : Rf 0.42, 0.32 (EtOAc/Hex/AcOH, 15:5:1);
 NMR : δ 7.4-7.2 (m, 5H), 5.71 (dd, J=15, 6Hz, 1H), 5.64 (dd, J=15, 8Hz, 1H), 4.35 (t, J=6Hz, 1H), 4.35 (t, J=6Hz, 1H), 3.95 (q, J=8Hz, 1H), 3.22 (s, 2H), 3.35-3.3 and 3.0-2.3 (m, 9H), 3.2-2.5 (br), 2.0-1.8 (m, 2H), 1.38 (d, J=6Hz, 3H).

Formulation Example


The following components were admixed in conventional method and dried. Microcrystalline cellulose was added to the mixture to obtain the total weight 10 g. The resulting mixture was mixed sufficiently to make it homogeneous and then tableted in conventional manner to give 100 tablets each containing 30 μ g of the active ingredient.

- a solution of 11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprost-13E-enoic acid (3 mg) in ethanol 10 ml
- magnesium stearate 100 mg
- silicon dioxide 20 mg

- . talc 10 mg
- . carboxymethylcellulose calcium 200 mg
- . microcrystalline cellulose 5.0 g

Claims

1. A 3,7-dithiaprostanoic acid derivative of the formula (I):



(wherein R¹ is hydroxy, C1-4 alkoxy or a group of the formula:



wherein R⁶ and R⁷, independently, are hydrogen atom or C1-4 alkyl,

R² is hydrogen atom or hydroxy,

R³ is

(i) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl,

(ii) phenyl or C3-7 cycloalkyl,

(iii) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by phenyl or C3-7 cycloalkyl,

with the proviso that, alkyl, alkenyl, alkynyl in (i) or (iii) may be substituted by one hydroxy group, when R² is hydrogen atom;

the symbol \equiv is a double or single bond;

the formula including the 8-epi equilibrium compound thereof);

a non-toxic salt thereof or a cyclodextrin clathrate thereof.

2. A compound according to claim 1, wherein R³ is C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl.
3. A compound according to claim 1, wherein R³ is phenyl or C3-7-cycloalkyl.
4. A compound according to claim 1, wherein R³ is C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by phenyl.
5. A compound according to claim 1, wherein R³ is C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by C3-7 cycloalkyl.
6. A compound according to claim 2, which is

11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprost-13E-enoic acid,
 11 α ,15 α -dihydroxy-9-oxo-17 β ,20-dimethyl-3,7-dithiaprost-13E-enoic acid,
 11 α ,15 α -dihydroxy-9-oxo-17 α ,20-dimethyl-3,7-dithiaprost-13E-enoic acid,
 11 α ,16 β -dihydroxy-9-oxo-16 α -methyl-3,7-dithiaprost-13E-enoic acid,
 11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprostanoic acid,
 11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprost-13E,17Z-dienoic acid
 11 α ,15 α -dihydroxy-9-oxo-15 β -methyl-3,7-dithiaprost-13E-enoic acid,
 11 α ,15 α -dihydroxy-9-oxo-17-ethyl-3,7-dithia-20-norprost-13E-enoic acid,
 11 α ,15 α -dihydroxy-9-oxo-3,7-dithia-20-norprost-13E-enoic acid,
 11 α ,15 α -dihydroxy-9-oxo-3,7-dithia-20-homoprost-13E-enoic acid,

11 α ,15 α -dihydroxy-9-oxo-16 β -methyl-3,7-dithiaprost-13E-enoic acid,
 11 α ,15 α -dihydroxy-9-oxo-3,7-dithiaprost-13E,19-dienoic acid,
 11 α ,15 α -dihydroxy-9-oxo-18-methyl-3,7-dithia-20-norprost-13E-enoic acid or
 11 α ,15 α -dihydroxy-9-oxo-16 α -methyl-3,7-dithiaprost-13E-enoic acid or methyl ester thereof.

7. A compound according to claim 3, which is

11 α ,15 α -dihydroxy-9-oxo-15-cyclohexyl-3,7-dithia-16,17,18,19,20-pentanorprost-13E-enoic acid or
 11 α ,15 α -dihydroxy-9-oxo-15-cyclopentyl-3,7-dithia-16,17,18,19,20-pentanorprost-13E-enoic acid
 or methyl ester thereof.


8. A compound according to claim 4, which is

11 α ,15 α -dihydroxy-9-oxo-16-phenyl-17,18,19,20-tetranor-3,7-dithiaprost-13E-enoic acid,
 11 α ,15 α -dihydroxy-9-oxo-17-phenyl-18,19,20-trinor-3,7-dithiaprost-13E-enoic acid or
 11 α ,15 α -dihydroxy-9-oxo-16 α -methyl-16-phenyl-3,7-dithia-20-norprost-13E-enoic acid or methyl ester there-
 of.


9. A compound according to claim 5, which is

11 α ,15 α -dihydroxy-9-oxo-16-cyclohexyl-3,7-dithia-17,18,19,20-tetranorprost-13E-enoic acid,
 11 α ,15 α -dihydroxy-9-oxo-19,20-methano-3,7-dithiaprost-13E-enoic acid or
 11 α ,15 α -dihydroxy-9-oxo-16-cyclopentyl-3,7-dithia-17,18,19,20-tetranorprost-13E-enoic acid
 or methyl ester thereof.

10. A process for the preparation of a compound of the formula (Ia):




(wherein all symbols are the same meaning as defined in claim 1)
 which comprises hydrolysis of a compound of the formula (Ib):




(wherein R¹⁰ is C1-4 alkyl and the other symbols are the same meaning as defined hereinbefore)
 with an enzyme.

11. A process for the preparation of a compound of the formula (Ic):



(wherein all symbols are the same meaning as defined in claim 1)
which comprises amidation of a compound of the formula (Ia):




(wherein all symbols are the same meaning as defined in claim 1)
with a compound of the formula (III):




(III)

wherein all symbols are the same meaning as defined in claim 1).

12. A process for the preparation of a compound of the formula (Ib):



(wherein all symbols are the same meaning as defined in claim 1)
which comprises hydrolysis of a compound of formula (II):



(wherein R^{2a} is hydrogen atom or hydroxy protected by a protecting group which is eliminated under an acidic condition, R^{3a} is (i) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl, (ii) phenyl or C3-7 cycloalkyl, (iii) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl which are substituted by phenyl or C3-7 cycloalkyl (with the proviso that when R^{2a} is hydrogen, alkyl, alkenyl and alkynyl groups in (I) or (iii) may be substituted by one hydroxy protected by a protecting group which is eliminated under an acidic condition);

the symbol:

5

is a double or single bond);
in an acidic condition.

10

13. A pharmaceutical composition which comprises, as active ingredient, a compound of the formula (I) depicted in claim 1 or cyclodextrin clathrate thereof or non-toxic salt thereof, with a pharmaceutical carrier or coating.

15

14. A compound of the formula (I) depicted in claim 11 or cyclodextrin clathrate thereof or non-toxic salt thereof, with a pharmaceutical carrier or coating for use in a method for the prevention and/or treatment of immunologic diseases (autoimmune diseases, immunological deficiency disease, organ transplantation), asthma, abnormal bone formation, neuronal cell death, liver damage, nephritis, hypertension or myocardiac ischemia.

20

25

30

35

40

45

50


55

THIS PAGE BLANK (USPTO)

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 855 389 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:

16.06.1999 Bulletin 1999/24

(51) Int Cl. 6: **C07C 405/00, A61K 31/557**

(43) Date of publication A2:

29.07.1998 Bulletin 1998/31

(21) Application number: **98300513.3**(22) Date of filing: **26.01.1998**

(84) Designated Contracting States:

**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

Designated Extension States:

AL LT LV MK RO SI(30) Priority: **27.01.1997 JP 2719897**(71) Applicant: **ONO PHARMACEUTICAL CO., LTD.**
Chuo-ku Osaka 541 (JP)


(72) Inventors:

- Maruyama, Toru,
c/o Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)
- Ohuchida, Shuichi,
Ono Pharmaceutical Co., Ltd.
Shimamoto-cho, Mishima-gun, Osaka, 618 (JP)

(74) Representative: **Bentham, Stephen**
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)

(54) **A 3,7-dithiaprostanic acid derivative**

(57) A 3,7-dithiaprostanic acid derivative of the formula (I)



(wherein R¹ is OH, C1-4 alkoxy, NR⁶R⁷ (wherein R⁶, R⁷ are H, C1-4); R² is H, OH; R³ is (i) alkyl, alkenyl, alkynyl (ii) phenyl, cycloalkyl (iii) alkyl, alkenyl, alkynyl substituted by phenyl, cycloalkyl (when R² is H, alkyl, alkenyl, alkynyl in (i) or (iii) may be substituted by OH) possesses a binding activity for PGE₂ receptor (especially for EP4). Therefore they are useful for the treatment and/or prevention of immunologic diseases (autoimmune diseases, organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, liver damage, nephritis, hypertension, myocardial ischemia etc.

EP 0 855 389 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 98 30 0513

DOCUMENTS CONSIDERED TO BE RELEVANT			Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages			
D, A	EP 0 051 284 A (TEIJIN LTD) 12 May 1982 * claims 1,30-37 *	1-14	C07C405/00 A61K31/557	
D, A	JP 58 148857 A (TEIJIN KK) 5 September 1983 * the whole document *			
D, A	JP 58 110562 A (TEIJIN KK) 1 July 1983 * the whole document *			
The present search report has been drawn up for all claims			<p>TECHNICAL FIELDS SEARCHED (Int.Cl.6)</p> <p>C07C</p>	
Place of search		Date of completion of the search	Examiner	
THE HAGUE		21 April 1999	Berte, M	
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>				

EPO FORM 1503 03/82 (P4/C01)

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 98 30 0513

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-04-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0051284 A	12-05-1982	JP 1040825 B	31-08-1989
		JP 1559138 C	16-05-1990
		JP 57165363 A	12-10-1982
		JP 1496482 C	16-05-1989
		JP 57077669 A	15-05-1982
		JP 63044143 B	02-09-1988
		JP 1023445 B	02-05-1989
		JP 1540535 C	31-01-1990
		JP 57108065 A	05-07-1982
		US 4466980 A	21-08-1984
JP 58148857 A	05-09-1983	NONE	
JP 58110562 A	01-07-1983	JP 1656528 C	13-04-1992
		JP 3007666 B	04-02-1991

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)